Tags : License


Prestige Biopharma and Pharmapark Sign an Exclusive License and Supply

Shots: Pharmapark to get exclusive rights to commercialize HD204 and is responsible for local registration, sales, and marketing of the biosimilar in Russia in collaboration with Russian import substitution strategy Prestige BioPharma will be responsible for commercial supply the product out of its manufacturing facilities in Osong, Korea Prestige’s (HD204) is currently being evaluated in […]Read More


Biogen Signs a License and Commercialization Agreement with Bio-Thera for

Shots: Bio-Thera to receive $30M up front following the achievement of P-III satisfactory results and is eligible for commercial milestones along with royalties. The transaction is expected to close in Q2’21 Biogen to get exclusive regulatory, manufacturing, and commercial rights of BAT1806 in all countries excluding China (includes Hong Kong, Macau, and Taiwan) Biogen will […]Read More


Sanofi Out Licenses Two Sickle Cell Disease Programs to GBT

Shots: Sanofi to receive ~$353M including $2.25M up front and remaining as development, regulatory and commercial milestones as well as royalties on WW net sales of programs GBT gets exclusive WW rights to two early-stage research programs in SCD. One program pursues a novel anti-sickling mechanism and the other leverages a new approach to reduce […]Read More

Biotech COVID-19

Sorrento Collaborates with Mount Sinai to Develop Ab Combination for

Shots: The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants The pre-clinical development of Ab combination (IV and intranasal) including Sorrento and Mount Sinai Abs is underway The collaboration follows Sorrento’s efforts to eradicate COVID-19 […]Read More


Exelixis Signs an Exclusive License Agreement with WuXi Biologics to

Shots: WuXi Bio to receive up front and is eligible for development & commercialization milestones, along with royalties on sales of any potential products commercialized from the panel Exelixis get an exclusive license to the panel of mAb against an undisclosed oncology target for biologics applications Exelixis leverages WuXi Bio’s integrated technology platforms to develop […]Read More


Merck KGaA Signs an Exclusive Worldwide License Agreement with Day

Shots: Merck KGaA to receive up front, additional regulatory, approval, and sales milestone along with royalties on sales of pimasertib and MSC2015103B. The agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of MEK inhibitors Day One plans to initiate a P-I/II study to evaluate the safety, tolerability, and preliminary efficacy […]Read More


Onward Signs a Worldwide Exclusive License and Co-Development Agreement with

Shots: Biomunex to receive up front, development, regulatory & sales milestones, equity investment along with royalties on sales of therapies Onward get the right to pursue development, manufacture & commercialize first-in-class bispecific Ab. The companies will jointly develop the Ab during the preclinical and early clinical program Biomunex is responsible for early preclinical development, while […]Read More


AbbVie Signs a License Agreement with Caribou Biosciences for CAR-T

Shots: Caribou to receive $40M up front in cash & equity investment, ~$300M in development, regulatory, and launch milestones along with additional commercial milestones and global royalties AbbVie will utilize and gets exclusive rights to Caribou’s next-generation Cas12a chRDNA genome editing and cell therapy technologies to develop two new CAR-T cell therapies directed to specified […]Read More


Pfizer Signs a License and Research Agreement with Imcyse to

Shots: Imcyse to receive up front, ~$180M as milestones along with royalties. Pfizer to purchase an equity stake in Imcyse Initially, the companies will collaborate to develop existing lead candidates and further optimize potential molecules. Later, Pfizer will lead clinical development and commercialization activities for the program The Imotope platform is a curative approach to […]Read More